peanut allergy

With Peanut Patch in FDA Purgatory, DBV Plans Layoffs to Stretch Cash
With Peanut Patch in FDA Purgatory, DBV Plans Layoffs to Stretch Cash
Xconomy
DBV Technologies
FDA
peanut allergy
layoffs
Viaskin Peanut
Flag link:
A Tale of 2 Biotechs With Competing Peanut Allergy Treatments
A Tale of 2 Biotechs With Competing Peanut Allergy Treatments
Motley Fool
peanut allergy
Viaskin Peanut
DBV Technologies
Aimmune Therapeutics
Palforzia
Flag link:
In another win for rival Aimmune, FDA presses pause on DBV's peanut patch with additional questions
In another win for rival Aimmune, FDA presses pause on DBV's peanut patch with additional questions
Endpoints
FDA
Aimmune
DBV Technologies
peanut allergy
Viaskin Peanut
Flag link:
DBV's peanut prevention patch approaches key stage of approval process
DBV's peanut prevention patch approaches key stage of approval process
Endpoints
DBV Technologies
peanut allergy
FDA
drug approvals
Viaskin Peanut
Flag link:
What Aimmune's Peanut Allergy Drug Approval Means for the Rest of the Pipeline
What Aimmune's Peanut Allergy Drug Approval Means for the Rest of the Pipeline
Motley Fool
Aimmune
FDA
peanut allergy
Palfozia
DBV Technologies
Flag link:
Aimmune wins approval for peanut immunotherapy, charges 10k+
Aimmune wins approval for peanut immunotherapy, charges 10k+
Endpoints
Aimmune
Palforzia
peanut allergy
FDA
Flag link:
FDA decision nears on Aimmune's contested peanut allergy drug
FDA decision nears on Aimmune's contested peanut allergy drug
BioPharma Dive
FDA
Aimmune
peanut allergy
Palforzia
DBV Technologies
Viaskin Peanut
Flag link:
Why the FDA's Decision on Aimmune's Peanut Allergy Drug Is Crucial for the Company -- and Patients
Why the FDA's Decision on Aimmune's Peanut Allergy Drug Is Crucial for the Company -- and Patients
Motley Fool
Aimmune Therapeutics
FDA
Palforzia
peanut allergy
patients
Flag link:
Stanford researchers pursue AnaptysBio's embattled IL-33 drug in peanut allergy
Stanford researchers pursue AnaptysBio's embattled IL-33 drug in peanut allergy
Fierce Biotech
Stanford University
AnaptysBio
peanut allergy
etokimab
Flag link:
Aimmune Presents New Peanut Allergy Data and Presses for Real-World Data Approaches
Aimmune Presents New Peanut Allergy Data and Presses for Real-World Data Approaches
BioSpace
Aimmune Therapeutics
peanut allergy
AR101
real world data
RWE
Flag link:
DBV Technologies announces FDA acceptance of BLA filing for Viaskin Peanut to treat peanut allergy
DBV Technologies announces FDA acceptance of BLA filing for Viaskin Peanut to treat peanut allergy
Pharmaceutical Business Review
Viaskin Peanut
DBV Technologies
FDA
peanut allergy
Flag link:
Allergists Debate Anticipated FDA Approval Of A Peanut Allergy Drug
Allergists Debate Anticipated FDA Approval Of A Peanut Allergy Drug
NPR
Aimmune Therapeutics
peanut allergy
Palforzia
Flag link:
Aimmune's peanut allergy drug secures FDA panel support, along with criticism
Aimmune's peanut allergy drug secures FDA panel support, along with criticism
Biopharma Dive
Aimmune
FDA
peanut allergy
advisory panel
Palforzia
AR 101
Flag link:
An FDA advisory panel is reviewing Aimmune’s peanut allergy therapy. Here’s what’s happening
An FDA advisory panel is reviewing Aimmune’s peanut allergy therapy. Here’s what’s happening
Stat
FDA
advisory panels
peanut allergy
Aimmune Therapeutics
Palforzia
Flag link:
No surprises in FDA staff review for Aimmune peanut allergy therapy — focus remains on safety, tolerability profile
No surprises in FDA staff review for Aimmune peanut allergy therapy — focus remains on safety, tolerability profile
Endpoints
Aimmune
FDA
peanut allergy
Palforzia
AR101
Flag link:
DBV Technologies Resubmits BLA for Peanut Allergy Treatment
DBV Technologies Resubmits BLA for Peanut Allergy Treatment
BioSpace
DBV Technologies
FDA
peanut allergy
Viaskin Peanut
Flag link:
New peanut allergy therapies aren’t as effective — or nearly as inexpensive — as abstinence, says ICER
New peanut allergy therapies aren’t as effective — or nearly as inexpensive — as abstinence, says ICER
Endpoints
peanut allergy
Aimmune Therapeutics
DBV Technologies
ICER
AR101
Viaskin Peanut
Flag link:
Vedanta Biosciences enrolls first patient in VE416 phase 1b/2 food allergy clinical study
Vedanta Biosciences enrolls first patient in VE416 phase 1b/2 food allergy clinical study
Pharmaceutical Business Review
Vedanta Biosciences
clinical trials
peanut allergy
VE416
Flag link:
FDA schedules Aimmune's peanut allergy drug for September expert review
FDA schedules Aimmune's peanut allergy drug for September expert review
Biopharma Dive
Aimmune Therapeutics
peanut allergy
FDA
AR101
Flag link:
Aimmune's peanut allergy immunotherapy clears European PhIII with flying colors, paving way for first US, EU therapeutic approval
Aimmune's peanut allergy immunotherapy clears European PhIII with flying colors, paving way for first US, EU therapeutic approval
Endpoints
Aimmune
peanut allergy
Europe
EMA
FDA
AR-101
Flag link:

Pages